DK1219609T3 - Aromatiske nitrogenholdige 6-leddede ringforbindelser - Google Patents

Aromatiske nitrogenholdige 6-leddede ringforbindelser

Info

Publication number
DK1219609T3
DK1219609T3 DK00960979T DK00960979T DK1219609T3 DK 1219609 T3 DK1219609 T3 DK 1219609T3 DK 00960979 T DK00960979 T DK 00960979T DK 00960979 T DK00960979 T DK 00960979T DK 1219609 T3 DK1219609 T3 DK 1219609T3
Authority
DK
Denmark
Prior art keywords
membered ring
ring compounds
aromatic nitrogen
aromatic
nitrogen
Prior art date
Application number
DK00960979T
Other languages
Danish (da)
English (en)
Inventor
Koichiro Yamada
Kenji Matsuki
Kenji Omori
Kohei Kikkawa
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26545273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1219609(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Application granted granted Critical
Publication of DK1219609T3 publication Critical patent/DK1219609T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00960979T 1999-09-16 2000-09-13 Aromatiske nitrogenholdige 6-leddede ringforbindelser DK1219609T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP26185299 1999-09-16
JP2000130371 2000-04-28
PCT/JP2000/006258 WO2001019802A1 (fr) 1999-09-16 2000-09-13 Composes cycliques aromatiques azotes a six elements

Publications (1)

Publication Number Publication Date
DK1219609T3 true DK1219609T3 (da) 2007-05-21

Family

ID=26545273

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00960979T DK1219609T3 (da) 1999-09-16 2000-09-13 Aromatiske nitrogenholdige 6-leddede ringforbindelser

Country Status (27)

Country Link
US (2) US6656935B2 (US07585860-20090908-C00154.png)
EP (1) EP1219609B1 (US07585860-20090908-C00154.png)
KR (1) KR100532546B1 (US07585860-20090908-C00154.png)
CN (2) CN1374953A (US07585860-20090908-C00154.png)
AR (1) AR025668A1 (US07585860-20090908-C00154.png)
AT (1) ATE358670T1 (US07585860-20090908-C00154.png)
AU (1) AU767558B2 (US07585860-20090908-C00154.png)
BE (1) BE2013C051I2 (US07585860-20090908-C00154.png)
BG (1) BG65453B1 (US07585860-20090908-C00154.png)
BR (1) BRPI0014526C1 (US07585860-20090908-C00154.png)
CA (1) CA2383466C (US07585860-20090908-C00154.png)
CY (2) CY1106534T1 (US07585860-20090908-C00154.png)
DE (1) DE60034239T2 (US07585860-20090908-C00154.png)
DK (1) DK1219609T3 (US07585860-20090908-C00154.png)
ES (1) ES2283315T3 (US07585860-20090908-C00154.png)
FR (1) FR13C0050I2 (US07585860-20090908-C00154.png)
HK (1) HK1044535A1 (US07585860-20090908-C00154.png)
HU (1) HU225917B1 (US07585860-20090908-C00154.png)
IL (2) IL148291A0 (US07585860-20090908-C00154.png)
LU (1) LU92249I2 (US07585860-20090908-C00154.png)
MY (1) MY123528A (US07585860-20090908-C00154.png)
NO (2) NO322038B1 (US07585860-20090908-C00154.png)
PT (1) PT1219609E (US07585860-20090908-C00154.png)
RU (1) RU2233273C3 (US07585860-20090908-C00154.png)
TR (1) TR200200701T2 (US07585860-20090908-C00154.png)
TW (1) TWI258471B (US07585860-20090908-C00154.png)
WO (1) WO2001019802A1 (US07585860-20090908-C00154.png)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
WO2001083460A1 (fr) * 2000-04-28 2001-11-08 Tanabe Seiyaku Co., Ltd. Composes cycliques
US20080027037A1 (en) * 2000-04-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Cyclic compounds
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
EP1316316B1 (en) 2000-09-06 2012-04-04 Mitsubishi Tanabe Pharma Corporation Preparations for oral administration
ATE415396T1 (de) * 2000-09-20 2008-12-15 Ortho Mcneil Pharm Inc Pyrazine derivate als tyrosin kinase modulatoren
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
JP4179784B2 (ja) * 2001-02-15 2008-11-12 田辺三菱製薬株式会社 口腔内速崩壊性錠
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
JP4460292B2 (ja) * 2001-10-17 2010-05-12 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
DE60221627D1 (de) * 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
US6924290B2 (en) * 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
US7176310B1 (en) * 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
WO2003094839A2 (en) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
US7057042B2 (en) 2002-05-29 2006-06-06 Abbott Laboratories Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
WO2003101994A1 (en) * 2002-05-29 2003-12-11 Abbott Laboratories Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
WO2004014365A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
CA2508914A1 (en) 2002-12-04 2004-06-17 Gene Logic Inc. Modulators of melanocortin receptor
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
JP2008536888A (ja) 2005-04-19 2008-09-11 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺高血圧症の治療のためのロフルミラスト
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20080051413A1 (en) * 2006-08-25 2008-02-28 Kaohsiung Medical University Nitrophenylpiperazine derivative of xanthine which relaxes tracheal airway and increases respiratory performance
NZ574710A (en) 2006-09-07 2012-02-24 Nycomed Gmbh Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
TW200914457A (en) * 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
PL2152663T3 (pl) 2007-06-04 2014-09-30 Ben Gurion Univ Of The Negev Research And Development Authority Związki triarylowe oraz kompozycje zawierające te związki
US8071557B2 (en) * 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
WO2009013286A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Organic compounds
EP2202228B1 (en) * 2007-10-15 2014-12-10 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
EP2082772A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082768A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082766A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Blister Strip Coil Forming
EP2082771A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082767A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
CA2718528C (en) * 2008-03-18 2016-10-25 Merck Sharp & Dohme Corp. Substituted 4-hydroxypyrimidine-5-carboxamides
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2444777T3 (es) 2009-06-12 2014-02-26 Bristol-Myers Squibb Company Compuestos de nicotinamida útiles como moduladores de quinasas
US8354593B2 (en) * 2009-07-10 2013-01-15 Nanocomp Technologies, Inc. Hybrid conductors and method of making same
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
EP2361911A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361912A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2556820A4 (en) 2010-04-05 2015-01-21 Sk Chemicals Co Ltd COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES
CN101798301A (zh) * 2010-04-13 2010-08-11 漆又毛 吡咯烷基嘧啶甲磺酰胺衍生物及制备方法
TW201210584A (en) 2010-08-18 2012-03-16 Alcon Res Ltd Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
CN102372697A (zh) * 2010-08-19 2012-03-14 山东轩竹医药科技有限公司 取代的嘧啶类化合物
JP5697800B2 (ja) * 2011-07-21 2015-04-08 シュエンジュウ・ファーマ・カンパニー・リミテッド 複素環置換ピリミジン化合物
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
KR101794321B1 (ko) 2012-08-14 2017-12-01 수안주 파마 코포레이션 리미티드 바이사이클릭 그룹 치환된 피리미딘 화합물
CA2892745A1 (en) 2012-11-28 2014-06-05 Grunenthal Gmbh Specific carboxamides as kcnq2/3 modulators
JP2016508118A (ja) * 2012-11-28 2016-03-17 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３モジュレーターとしての置換アミノ−アリールカルボキサミド
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
CN104059025B (zh) * 2013-03-20 2017-07-04 广州朗圣药业有限公司 一种用于制备阿伐那非的中间体及其制备方法
KR101749314B1 (ko) 2013-03-29 2017-07-03 수안주 파마 코포레이션 리미티드 비사이클릭-치환된 피리미딘 타입 pde-5 억제제의 프로드러그
WO2014174529A2 (en) * 2013-04-23 2014-10-30 Hetero Research Foundation Polymorphs of avanafil
CN103254180B (zh) * 2013-05-23 2014-07-23 苏州明锐医药科技有限公司 一种阿伐那非的制备方法
WO2014187273A1 (zh) 2013-05-23 2014-11-27 苏州明锐医药科技有限公司 阿伐那非的制备方法
CN103265534B (zh) * 2013-05-23 2014-07-23 苏州明锐医药科技有限公司 阿伐那非的制备方法
CN103254179B (zh) * 2013-05-23 2014-09-10 苏州明锐医药科技有限公司 阿伐那非的制备方法
WO2015001567A1 (en) * 2013-07-01 2015-01-08 Msn Laboratories Private Limited Process for the preparation of (s)-4-[(3-chloro-4-methoxybenzyl)amino]-2-[2- (hydroxymethyl)-1-pyrrolidinyl]-n-(2-pyrimidinyl methyl-5-pyrimidine carboxamide
CN104557877B (zh) * 2013-10-28 2016-08-17 重庆安格龙翔医药科技有限公司 一种阿伐那非中间体及其制备方法和应用
US10111880B2 (en) 2013-11-05 2018-10-30 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
CN104628708A (zh) * 2013-11-13 2015-05-20 北大方正集团有限公司 一种阿伐那非的晶型及其制备方法、用途和药物组合物
CN104628707A (zh) * 2013-11-13 2015-05-20 北大方正集团有限公司 一种阿伐那非的无定型及其制备方法、用途和药物组合物
CN104650045B (zh) * 2013-11-19 2017-04-19 苏州旺山旺水生物医药有限公司 阿伐那非的制备方法
GB201321748D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN103833736A (zh) * 2014-03-04 2014-06-04 北京澳合药物研究院有限公司 一种阿伐那非的制备方法
WO2015177807A1 (en) * 2014-05-22 2015-11-26 Wanbury Ltd. A process for the preparation of avanafil and its novel intermediates
CN104003981A (zh) * 2014-05-28 2014-08-27 河北康泰药业有限公司 阿伐那非的合成方法
CN104151299B (zh) * 2014-08-22 2017-03-08 北京科莱博医药开发有限责任公司 化合物、晶型化合物及其制备方法
CN104356115B (zh) * 2014-11-21 2016-08-24 齐鲁天和惠世制药有限公司 一种4-[(3-氯-4-甲氧基苄基)氨基]-2-[2-(羟甲基)-1-吡咯烷基]嘧啶-5-羧酸乙酯的制备方法
CN104530015B (zh) * 2014-12-10 2017-01-04 齐鲁天和惠世制药有限公司 一种阿伐那非的制备方法
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN105924402A (zh) * 2016-05-06 2016-09-07 蚌埠中实化学技术有限公司 一种2-胺基甲基嘧啶盐酸盐的制备方法
BR112019000589A2 (pt) 2016-07-14 2019-04-24 Pfizer Inc. pirimidina carboxamidas como inibidores da enzima vanina-1
CN106496201A (zh) * 2016-10-31 2017-03-15 昆药集团股份有限公司 一种阿伐那非原料药的制备方法
BR112019012251A2 (pt) 2016-12-14 2019-11-05 Respira Therapeutics Inc métodos e composições para tratamento de hipertensão pulmonar e outros distúrbios pulmonares
CN107879986A (zh) * 2017-12-20 2018-04-06 重庆英斯凯化工有限公司 一种阿伐那非杂质的合成方法
CN108658872B (zh) * 2018-05-03 2021-06-22 无锡富泽药业有限公司 一种阿伐那非中间体的制备方法
CN112566670A (zh) 2018-08-06 2021-03-26 尼科斯股份有限公司 一氧化氮释放第5型磷酸二酯酶抑制剂
CN109280049B (zh) * 2018-09-25 2021-02-02 重庆奥舍生物化工有限公司 一种医药化合物阿伐那非的合成方法
CN109776505B (zh) * 2019-03-14 2021-07-27 扬州市三药制药有限公司 一种阿伐那非的制备方法
CN110078713B (zh) * 2019-04-10 2021-06-04 北京精华耀邦医药科技有限公司 一种用于治疗男性勃起功能障碍的化合物
CN110117274A (zh) * 2019-05-08 2019-08-13 梯尔希（南京）药物研发有限公司 一种阿伐那非杂质的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1229413A (US07585860-20090908-C00154.png) * 1967-06-14 1971-04-21
JPS5481299A (en) * 1977-12-09 1979-06-28 Daito Koeki Kk Preparation of 2,8-disubstituted-6-formyl-5,8-dihydro-5- oxopyrido 2,3-d pyrimidine derivative
AT392789B (de) * 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
DE3752141T2 (de) * 1986-02-24 1998-03-26 Mitsui Petrochemical Ind Mittel zur behandlung von neuropathie
DE69115126T2 (de) 1990-05-16 1996-05-09 Tomoegawa Paper Mfg Co Ltd Leitfähiges Substrat und seine Verwendung in den Druckmedien.
GB9012316D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
US5252604A (en) 1992-07-10 1993-10-12 Hoffmann-La Roche Inc. Compositions of retinoic acids and tocopherol for prevention of dermatitis
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
DE69408750T2 (de) * 1993-08-26 1998-07-23 Ono Pharmaceutical Co 4-Aminopyrimidin Derivate
AU694465B2 (en) 1993-12-27 1998-07-23 Eisai Co. Ltd. Anthranilic acid derivative
EP0722936B1 (en) 1994-08-09 2004-05-19 Eisai Co., Ltd. Fused pyridazine compound
KR100239800B1 (ko) 1996-11-28 2000-03-02 손경식 4,5-디아미노 피리미딘 유도체 및 이의 제조방법
JP2000072751A (ja) * 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd イソキノリノン誘導体
IL132406A0 (en) 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
GB9823101D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds

Also Published As

Publication number Publication date
HUP0202795A3 (en) 2003-03-28
NO322038B1 (no) 2006-08-07
BG106566A (en) 2003-02-28
BG65453B1 (bg) 2008-08-29
EP1219609B1 (en) 2007-04-04
FR13C0050I2 (fr) 2014-04-11
BR0014526B1 (pt) 2013-09-10
BE2013C051I2 (US07585860-20090908-C00154.png) 2019-10-16
LU92249I2 (fr) 2013-09-10
WO2001019802A1 (fr) 2001-03-22
CY2013034I2 (el) 2017-03-15
DE60034239T2 (de) 2007-12-27
HUP0202795A2 (hu) 2003-02-28
CN1374953A (zh) 2002-10-16
LU92249I9 (US07585860-20090908-C00154.png) 2019-01-03
US20030032647A1 (en) 2003-02-13
NO20021308L (no) 2002-04-24
ES2283315T3 (es) 2007-11-01
US6656935B2 (en) 2003-12-02
CY1106534T1 (el) 2012-01-25
US6797709B2 (en) 2004-09-28
KR100532546B1 (ko) 2005-12-01
IL148291A0 (en) 2002-09-12
BRPI0014526C1 (pt) 2021-05-25
DE60034239D1 (de) 2007-05-16
NO2013018I2 (no) 2015-01-12
TWI258471B (en) 2006-07-21
RU2233273C2 (ru) 2004-07-27
HK1044535A1 (en) 2002-10-25
BRPI0014526B8 (pt) 2017-03-21
AU767558B2 (en) 2003-11-13
IL148291A (en) 2006-10-05
CA2383466A1 (en) 2001-03-22
NO20021308D0 (no) 2002-03-15
RU2233273C3 (ru) 2019-07-17
CA2383466C (en) 2009-08-25
EP1219609A4 (en) 2002-11-06
HU225917B1 (en) 2007-12-28
ATE358670T1 (de) 2007-04-15
NO2013018I1 (no) 2014-06-02
FR13C0050I1 (US07585860-20090908-C00154.png) 2013-09-27
CN102584799A (zh) 2012-07-18
MY123528A (en) 2006-05-31
KR20020047170A (ko) 2002-06-21
AR025668A1 (es) 2002-12-11
TR200200701T2 (tr) 2002-06-21
EP1219609A1 (en) 2002-07-03
AU7311800A (en) 2001-04-17
US20030229095A1 (en) 2003-12-11
CY2013034I1 (el) 2016-04-13
BR0014526A (pt) 2002-06-18
PT1219609E (pt) 2007-06-19

Similar Documents

Publication Publication Date Title
DK1219609T3 (da) Aromatiske nitrogenholdige 6-leddede ringforbindelser
CY2015037I1 (el) Ενωσεις αζωτουχου αρωματικου δακτυλιου
EE200100502A (et) Ühendid
EE200200033A (et) Uued ühendid
EE200200082A (et) Uued spiroühendid
DK1261585T3 (da) Substituerede indol-Mannichbaser
EE200200224A (et) Uudsed ühendid
ATE305470T1 (de) Naphthyridinverbindungen
IS6139A (is) Ný efnasambönd
NO20023013L (no) Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer
NO20013769L (no) Kalsilytiske forbindelser
NO20020466L (no) Kalsilytiske forbindelser
NO20014095D0 (no) 2-aminopyridiner inneholdende kondenserte ringsubstituenter
IS6141A (is) Ný efnasambönd
NO20014262D0 (no) Tiazoloindolinon-forbindelser
ID29984A (id) Senyawa-senyawa bis-stirilbifenil
ES1042450Y (es) Llavero perfeccionado
UA3605S (uk) Стопорне кільце
NO992717D0 (no) Gassoverf°ringsanordning
SE9902762D0 (sv) New compounds
SE9904420D0 (sv) New compounds
SE9900071D0 (sv) New compounds
SE9900086D0 (sv) New compounds
SE9904228D0 (sv) New compounds
SE9904418D0 (sv) New compounds